The main point I was trying to make wasn't so much that Cerevel is a good valuation comparison for Neuren, but rather that you don't have to have an approved drug on the market to have a high valuation.
There have been many comments from posters (and analysts) suggesting NNZ-2591 is still valued low because it's not yet approved.
It’s patently silly to say that a company can’t have a high valuation unless it has an approved drug on the market.
Another example of a pre-approval biotech being acquired for a high valuation was Karuna Therapeutics, which was acquired by BMS for US$14 bn a year prior to Cerevel’s US$8.7 bn acquisition by AbbVie.
Karuna’s drugs were in similar indications to Cerevel’s but its lead drug, while not yet approved, had already succeeded in a registrational trial and was already under regulatory review with the FDA.
Comparing what was paid for Karuna (US$14 bn) versus what was paid for Cerevel (US$8.7 bn), one might argue that having successful pivotal trial results in hand seems to add a big chunk to valuations.
The way I see it, although it is possible for decent valuations to be achieved prior to market approval of the lead asset, substantially higher valuations can be achieved by a company where the target asset has already succeeded in a pivotal trial.
The US$7.3 bn paid for Reata Pharmaceuticals’ orphan drug asset doubtlessly reflected the certainty and near-term revenues that comes with having an already-approved drug.
I’d also point out that, despite the lofty prices paid for Reata, Cerevel and Karuna, all were acquired for a share price premium of less than 100%.
- Forums
- ASX - By Stock
- Neuren Media and Analyst Coverage
The main point I was trying to make wasn't so much that Cerevel...
-
- There are more pages in this discussion • 145 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$13.61 |
Change
0.280(2.10%) |
Mkt cap ! $1.739B |
Open | High | Low | Value | Volume |
$13.49 | $13.64 | $13.30 | $4.821M | 356.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 3602 | $13.55 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.66 | 1655 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 3602 | 13.550 |
1 | 4057 | 13.540 |
1 | 1947 | 13.530 |
1 | 1676 | 13.520 |
1 | 1947 | 13.510 |
Price($) | Vol. | No. |
---|---|---|
13.660 | 1655 | 2 |
13.690 | 1947 | 1 |
13.700 | 1000 | 1 |
13.720 | 1947 | 1 |
13.740 | 1947 | 1 |
Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |